[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017004127A - Metodos para evaluar el riesgo de desarrollar cancer de mama. - Google Patents

Metodos para evaluar el riesgo de desarrollar cancer de mama.

Info

Publication number
MX2017004127A
MX2017004127A MX2017004127A MX2017004127A MX2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A
Authority
MX
Mexico
Prior art keywords
methods
breast cancer
developing breast
assessing risk
risk
Prior art date
Application number
MX2017004127A
Other languages
English (en)
Inventor
Allman Richard
Original Assignee
Genetic Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Tech Limited filed Critical Genetic Tech Limited
Publication of MX2017004127A publication Critical patent/MX2017004127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

La invención actual se refiere a métodos y sistemas para evaluar el riesgo de un sujeto del sexo femenino humano para desarrollar cáncer de mama. En particular, la descripción actual se refiere a combinar la evaluación de riesgo clínico y la evaluación de riesgo genético para mejorar el análisis de riesgo, en donde la evaluación de riesgo genético comprende seleccionar al menos (72) polimorfismos de nucleótido sencillo (SNPs) descritos en la presente, o SNPs en desequilibrio de ligación con uno o más de los mismos.
MX2017004127A 2014-09-30 2015-09-29 Metodos para evaluar el riesgo de desarrollar cancer de mama. MX2017004127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (1)

Publication Number Publication Date
MX2017004127A true MX2017004127A (es) 2017-10-24

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004127A MX2017004127A (es) 2014-09-30 2015-09-29 Metodos para evaluar el riesgo de desarrollar cancer de mama.

Country Status (11)

Country Link
US (2) US10920279B2 (es)
EP (1) EP3201360A4 (es)
JP (1) JP6820838B2 (es)
KR (1) KR102334702B1 (es)
CN (1) CN107002138B (es)
AU (2) AU2015327756B2 (es)
CA (1) CA2962691C (es)
IL (1) IL251376B (es)
MX (1) MX2017004127A (es)
SG (1) SG11201702416YA (es)
WO (1) WO2016049694A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2463388T3 (en) 2005-11-29 2018-02-26 Cambridge Entpr Ltd Markers for breast cancer
CN102712949B (zh) 2009-06-01 2015-12-16 遗传技术有限公司 用于乳腺癌风险评估的方法
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20200102617A1 (en) * 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
JP2020536585A (ja) * 2017-10-13 2020-12-17 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの評価法
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克（北京）生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
KR20230019872A (ko) * 2020-05-27 2023-02-09 지네틱 테크놀로지스 리미티드 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN114283883B (zh) * 2021-12-27 2022-11-22 上海华测艾普医学检验所有限公司 基于分子标记的用于肝癌筛查和风险预测的系统及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
ATE428801T1 (de) 1996-06-04 2009-05-15 Univ Utah Res Found Überwachung der hybridisierung während pcr
EP0943017B1 (en) 1996-11-07 2001-01-31 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
JP2003501005A (ja) 1998-12-02 2003-01-14 キバ ジェネティックス，インコーポレイテッド 遺伝子型を用いた処置研究における分散を減少させる方法
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
CA2417407A1 (en) 2000-07-25 2002-01-31 Dz Genes Llc Diagnostic polymorphisms for the ecnos promoter
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US20040002071A1 (en) 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
JP2007503836A (ja) 2003-09-04 2007-03-01 インタージェネティックス インコーポレイテッド 癌のリスク層別化のための遺伝的解析法
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
DK2463388T3 (en) 2005-11-29 2018-02-26 Cambridge Entpr Ltd Markers for breast cancer
JP2010512729A (ja) 2006-06-23 2010-04-30 インタージェネティクス， インコーポレイテッド 癌リスクの層別化のための遺伝的モデル
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
CN101874120B (zh) 2007-03-26 2015-01-14 解码遗传学私营有限责任公司 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
MX2009012722A (es) 2007-05-25 2009-12-11 Decode Genetics Ehf Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2009009752A2 (en) 2007-07-11 2009-01-15 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
AU2009279434A1 (en) 2008-08-08 2010-02-11 Navigenics, Inc. Methods and systems for personalized action plans
JP2012502398A (ja) 2008-09-12 2012-01-26 ナビジェニクス インコーポレイティド 複数の環境的リスク因子及び遺伝的リスク因子を組み込む方法及びシステム
CN102712949B (zh) 2009-06-01 2015-12-16 遗传技术有限公司 用于乳腺癌风险评估的方法
CA2766210A1 (en) * 2009-06-25 2010-12-29 Yale University Single nucleotide polymorphisms in brca1 and cancer risk
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20200102617A1 (en) 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
JP2020536585A (ja) 2017-10-13 2020-12-17 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの評価法

Also Published As

Publication number Publication date
CA2962691C (en) 2023-05-23
AU2015327756B2 (en) 2018-01-04
US10920279B2 (en) 2021-02-16
US20180305764A1 (en) 2018-10-25
KR102334702B1 (ko) 2021-12-06
US10683549B2 (en) 2020-06-16
AU2015327756A1 (en) 2017-04-13
EP3201360A4 (en) 2018-05-09
CA2962691A1 (en) 2016-04-07
KR20170063977A (ko) 2017-06-08
AU2018202299A1 (en) 2018-04-26
US20160222469A1 (en) 2016-08-04
AU2018202299B9 (en) 2020-03-05
EP3201360A1 (en) 2017-08-09
WO2016049694A1 (en) 2016-04-07
AU2018202299B2 (en) 2019-10-24
JP6820838B2 (ja) 2021-01-27
IL251376A0 (en) 2017-05-29
CN107002138B (zh) 2022-06-14
SG11201702416YA (en) 2017-04-27
IL251376B (en) 2022-09-01
JP2017529859A (ja) 2017-10-12
CN107002138A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
MX2011012913A (es) Métodos para evaluar el riesgo de cáncer de mama.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
MX2017004927A (es) Metodos de evaluacion genomica en ganado.
TW201612518A (en) Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
WO2016176451A3 (en) System and method for processing genotype information relating to nsaid risk
MX352296B (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
WO2015004328A3 (en) Method and a kit for assessment of vitamin e need
UA104426U (uk) Спосіб прогнозування зрощення перелому
UA95978U (uk) Спосіб прогнозування зрощення перелому
PLOS Neglected Tropical Diseases Staff Correction: Development of Assays Using Hexokinase and Phosphoglucomutase Gene Sequences That Distinguish Strains of Leishmania tropica from Different Zymodemes and Microsatellite Clusters and Their Application to Palestinian Foci of Cutaneous Leishmaniasis
UA96535U (uk) Спосіб прогнозування зрощення перелому
UA96597U (uk) Спосіб прогнозування зрощення перелому
UA104418U (uk) Спосіб прогнозування зрощення перелому
UA106731U (uk) Спосіб прогнозування зрощення перелому
WO2016094854A3 (en) Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
UA96128U (uk) Спосіб прогнозування зрощення перелому
UA95602U (uk) Спосіб прогнозування зрощення перелому
UA97860U (uk) Спосіб прогнозування зрощення перелому
UA96595U (uk) Спосіб прогнозування зрощення перелому